Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 2/20 | 0.46 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30105853 | 1.00 | MAPT (0.62) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL6966954 | 0.90 | HTR5A (0.53) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL8133079 | 0.89 | MEN1 (0.53) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL407439 | 0.81 | NPC1 (0.70) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL25463085 | 0.78 | HTR5A (0.44) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL11927572 | 0.77 | HTR5A (0.53) | MAPTGAAHTR5ACSNK1G1ALDH1A1 | |
| SCHEMBL19224992 | 0.77 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL6964275 | 0.77 | MAPT (0.62) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL29485904 | 0.77 | MAPT (0.62) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL29485939 | 0.77 | MAPT (0.62) | MAPTMEN1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | disclosed |
| US-6569849-B1 | N-Substituted azaheterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| US-6004961-A | ANTIINFLAMMATORY AGENTS, ANALGESICS; NON-INSULIN-DEPENDENT DIABETES; AGE-RELATED OBESITY; DIBENZO(D,G)(1,3,6)DIOXAZOCINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-12-21 | — | — | US | disclosed |
| EP-0934306-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998015546-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | BACE1, BACE2, APP | MAPT 18/4885MEN1 1510/4885KMT2A 3744/4885 |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | MAPT 18/4885MEN1 1461/4885KMT2A 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.